AxioMed... is now raising growth capital to ramp up demand for orders already placed, and to have additional inventory to immediately expand market share against inferior ball and socket discs.
BOSTON (PRWEB) December 27, 2018
AxioMed completed its initial production of the first 60 cervical discs for implantation at its new Boston facility, and is now raising growth capital to ramp up demand for orders already placed, and to have additional inventory to immediately expand market share against inferior ball and socket discs. The capital raise is targeted to qualified private investors with a $50,000 minimum per investor. This sum encourages more participation vs. institutions with deeper pockets because Dr. Chin, Managing Partner and CEO of KICVentures (AxioMed's parent company) believes this disc should have a grass roots success story.
About AxioMed LLC
AxioMed was founded to advance the standard of care for patients with degenerative spine conditions by progressing spine technology beyond fusion and first-generation artificial discs. Led by an experienced surgeon team and utilizing patented viscoelastic polymer technology, AxioMed has developed the next generation of artificial discs. AxioMed completed its U.S. IDE for the Lumbar Disc with over five years of clinical follow-up.
KICVentures is a private investment company founded in 2005 by Harvard-trained Orthopedic Surgeon & Professor Dr. Kingsley R. Chin, who brings unique experience at the intersection of medicine, business and information technology. KICVentures is equipped with a strong advantage in identifying niche healthcare opportunities, and is headquartered in Boston, Mass.